Revance Therapeutics appoints new CMO
This article was originally published in Scrip
Executive Summary
Revance Therapeutics, a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, has named Arthur P Bertolino executive vice-president and chief medical officer. Dr Bertolino, a Board Certified dermatologist and dermatology industry executive, will join the company on 2 September 2014. Most recently he was vice-president of dermatology for Novartis Institutes for Biomedical Research (NIBR).
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.